IMB0901 is a small molecule myostatin (MSTN) inhibitor that inhibits the MSTN promoter activity, the MSTN signaling pathway, and the MSTN positive feedback regulation.
IMB0901 at a concentration of 2.5 or 5 μM significantly neutralized the MSTN signaling pathway triggered by 10 ng/ml MSTN.
IMB0901 at a dose of 5 μM significantly inhibited the P-SMAD and increased the P-FOXO3a in atrophied C2C12 myotubes.
IMB0901 upregulated the expressions of myotube markers and protected the myotube morphology.
IMB0901 lowered the expressions of Atrogin-1, MuRF-1, and ubiquitin and promoted phosphorylation of AKT, mTOR, and P70S6K in atrophied C2C12 myotubes.
IMB0901 (30 mg/kg) inhibited the weight loss of body, quadriceps, and gastrocnemius induced by C26 tumor model, decreased the expression of two E3 ligases Atrogin-1 and MuRF-1 in the quadriceps in vivo.
IMB0901 is a promising leading compound for the management of muscle atrophy induced by cancer cachexia.